%0 Journal Article
%T ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
%A Byung Ho Nam
%A Geon Kook Lee
%A Ji-Youn Han
%A Jin Soo Lee
%A Kun Young Lim
%A Young Ju Lee
%J Archive of "Cancer Research and Treatment : Official Journal of Korean Cancer Association".
%D 2017
%R 10.4143/crt.2016.365
%X We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC)
%K ERCC1
%K Platinum
%K Non-small-cell lung carcinoma
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512356/